Q-omics provides the consensus-scored NMTRQ-TTG12-1 profile across patient tissues and cancer cell-line models. NMTRQ-TTG12-1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, NMTRQ-TTG12-1 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, NMTRQ-TTG12-1 RNA expression shows 4,381 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight CESC, BRCA, and KIRC as cancer lineages where NMTRQ-TTG12-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NMTRQ-TTG12-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NMTRQ-TTG12-1 survival associations across molecular data types. NMTRQ-TTG12-1 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NMTRQ-TTG12-1 RNA expression–survival associations across cancer types. High NMTRQ-TTG12-1 expression shows unfavorable associations in CESC, HNSC, LUSC, CHOL and COAD, but favorable associations in KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for NMTRQ-TTG12-1 RNA expression.
This table summarizes NMTRQ-TTG12-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NMTRQ-TTG12-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NMTRQ-TTG12-1 shows lower tumor expression in BRCA and KIRC. The BRCA box plot shows higher NMTRQ-TTG12-1 RNA expression in normal versus tumor tissue (log2 FC = −0.092, t-test p = .005).
This table shows molecular features associated with NMTRQ-TTG12-1 in patient tissues and cancer cell lines. In patient samples, NMTRQ-TTG12-1 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
